All In Biotech

Free tool

FAERS Monitor: Depo-Subq Provera 104

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021583 or its brand name (Depo-Subq Provera 104, Medroxyprogesterone Acetate). Reports on generic versions are filed under their own applications.

Reports

10,076

Serious

8,739

87% of reports

Hospitalization

1,213

Death reported

311

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • breast cancer female2,993
  • breast cancer1,819
  • meningioma844
  • breast cancer metastatic434
  • drug ineffective309
  • off label use235
  • oestrogen receptor assay positive215
  • pain200
  • ovarian cancer186
  • nausea183
  • progesterone receptor assay positive178
  • fatigue167
  • headache153
  • vomiting151
  • breast cancer in situ137

Reports by year received

View as table
YearReports
20041,186
2005855
2006782
2007197
2008300
2009481
20101,841
2011504
2012280
201389
201472
2015123
2016122
2017113
2018153
2019217
2020272
2021212
2022200
2023240
2024347
2025791
2026699

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,083 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
progesterone receptor assay positiveSignal178491.7418.270,168
oestrogen receptor assay positiveSignal215488.6421.784,396
breast cancer femaleSignal2,993263.2254.8695,041
breast cancer in situSignal137252.1211.430,351
meningiomaSignal844119.2111.593,546
breast cancer metastaticSignal43487.980.035,721
ovarian cancerSignal18643.037.27,430
breast cancerSignal1,81941.539.870,821
pain2000.70.631
vomiting1510.70.625
off label use2350.60.584
headache1530.50.474
drug ineffective3090.50.4175
nausea1830.50.4105
fatigue1670.40.4118

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.